More convenient and less risky for patients than proper, traditional ones, liquid biopsies are being rapidly adopted; they can be performed on a serial basis and, in theory, give more complete information. However, doubts were [more]
The Cancer World team hopes that all our readers have had a good start to 2018. We look forward to bringing you critical, independent and rounded coverage of the big stories affecting quality cancer care [more]
A growing body of literature has described the so called “financial toxicity” of cancer, a common consequence of treatments, that sometimes leads patients to bankruptcy, and affects quality of life and clinical outcomes. “We don’t [more]
The National Cancer Institute of Argentina announced that its President Roberto Pradier passed away. Dr. Roberto Pradier obtained a Medical degree from the School of Medicine, University of Buenos Aires (UBA) in 1955. He received his [more]
The enhanced tactile sensitivity of blind and visually impaired women might make them especially suitable for breast examination, according to a visionary German gynaecologist. If it’s true that mammography is an effective breast cancer screening [more]
In the golden age of computing, both the present and future of medical decision-making seem to depend on new mathematical models and systems built around artificial intelligence (AI). But how will doctors and patients feel [more]
“A room full of healers.” This is how Larry Norton, Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering, described the feel of the auditorium during the 4th Advanced Breast Cancer [more]
Should regulators insist on robust evidence that a new drug shows clear benefit to patients as a condition of approval, or are demands for such levels of certainty unrealistic, or even unethical? Marc Beishon reports [more]
‘Value’ is the latest buzzword in cancer: value-based pricing, delivering value for cancer care, enhancing the value offering for cancer technologies… It makes sense, as focusing on the value of interventions we invest in is [more]
Could tailoring treatments to broad taxonomies work where targeting individual – or even multiple – genetic mutations has not? A growing number of researchers working on specific tumour types and/or across tumours believe this integrative [more]
Most solid tumours will prove fatal if they are not treated with surgery and/or radiotherapy and medical therapies. But evidence is building to show that treating the primary may raise the risk of metastatic spread. [more]
Legislators and policy makers could do a lot more to promote cancer research if they understood that improving treatment strategies is not all about new drugs, and that patients and health budgets pay a high [more]
Cancer patients are put at risk unless the surgeons who operate on them understand the principles of the disease, work closely with other oncology disciplines, and know which patients need to be referred to high-volume [more]